Last reviewed · How we verify

NCT04999228

Top Down Versus Step up in Pediatric Ulcerative Colitis

Recruiting now Phase 4 Last updated 28 February 2024
What this trial tests

Phase 4 trial testing Infliximab in Ulcerative Colitis in 40 participants. Currently enrolling.

Timeline
1 November 2021
Primary endpoint
1 June 2025
31 December 2026

Quick facts

Lead sponsorChildren's Hospital of Fudan University
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment40
Start date1 November 2021
Primary completion1 June 2025
Estimated completion31 December 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital of Fudan University

Who can join

Adults 6 to 18, any sex, with Ulcerative Colitis or Infliximab. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pediatric Ulcerative Colitis (UC) patients with moderate to severe disease activity at high risk of colectomy. Early use of biologic agents will likely be more effective. But there were no studies identified that compared a strategy of upfront biologic-based therapy versus gradual step-up therapy. In our study, newly diagnosed moderate to severe pediatric UC patients (6-18 years old) will be randomly divided into infliximab (IFX) treatment group (Top down group, TD) and corticosteroids (CS) treatment group (Step-up group, SU). Mucosal healing rate at week 12 will be compared between the two groups. The relapse rates and sustained durations of remission within one year will also be evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Infliximab

Trials testing the same drug.

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

Other Children's Hospital of Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04999228.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing